Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs)

Bioorg Med Chem. 2017 Jan 15;25(2):523-527. doi: 10.1016/j.bmc.2016.11.028. Epub 2016 Nov 19.

Abstract

Dendrimers are efficient drug delivery systems particularly useful in ocular diseases. In particular, low generation PAMAM dendrimers are non-toxic and non-immunogenic and they provide an enhancement of the residence time of drugs in the eyes. In this context, the synthesis of the PAMAM-based matrix metalloproteinases inhibitor 5, is reported. In particular, we demonstrated that 5 strongly binds (18.0nM±2.5nM) MMP-9, the most relevant MMP responsible of ocular surface damages in induced dry eyes syndrome (DES).

Keywords: Dendrimers; Inhibitors; Metalloproteins; NMR spectroscopy; Sulphonamidic scaffold.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites / drug effects
  • Dendrimers / chemical synthesis
  • Dendrimers / chemistry
  • Dendrimers / pharmacology*
  • Dose-Response Relationship, Drug
  • Fluorometry
  • Humans
  • Matrix Metalloproteinase 9 / isolation & purification
  • Matrix Metalloproteinase 9 / metabolism*
  • Matrix Metalloproteinase Inhibitors / chemical synthesis*
  • Matrix Metalloproteinase Inhibitors / chemistry
  • Matrix Metalloproteinase Inhibitors / pharmacology*
  • Molecular Structure
  • Structure-Activity Relationship

Substances

  • Dendrimers
  • Matrix Metalloproteinase Inhibitors
  • PAMAM Starburst
  • Matrix Metalloproteinase 9